A dvances in pharmacology often result from identifying the mechanism of action of drugs found empirically to be biologically active (1) . γ-Hydroxybutyric acid (GHB), also known as Fantasy, is a centrally active agent that has been used clinically and recreationally for nearly half a century. Because of its history of abuse, its availability is tightly regulated, although it is prescribed for the treatment of alcoholism and narcolepsy. Depending on the dose, GHB displays a myriad of effects on CNS function. Despite decades of research, significant questions remain about its mechanism of action. In PNAS, Absalom et al. (2) identify a distinct population of extrasynaptic GABA A receptors as a target for GHB, providing unique insights into the molecular target for this agent.
GHB and GABA An involvement of GABAergic systems in the actions of GHB has been suspected for some time because it is structurally similar to, and a metabolite of, GABA (3). Highand low-affinity [ 3 H]GHB binding sites are present in rat and human brain (4, 5 At least some of the pharmacological effects of GHB are due to its activation of extrasynaptic GABA A receptors.
Alternatively, these results might indicate that the [ 3 H]GHB binding site is of no physiological or pharmacological consequence. This appears unlikely, however, because in vivo studies with NCS-382 suggest that it interacts with a functional receptor; that is, NCS-382 administration diminishes the sedative and cataleptic effects of GHB and blocks the enhancing effects on the spontaneous firing rate of cortical neurons at low doses of GHB but not the depressant effects seen at higher doses (14, 15) . Because NCS-382 administration blocks neither GHB-induced ataxia nor its depressant effects on locomotor activity, learned and unlearned behavior, and operant responses (16, 17) , these actions are probably mediated by GHB activation of GABA B receptors.
Efforts to characterize the GHB binding site led to the identification of two parent clones (18 /δ-and β 1 -subunits. They report that the α 4 /δ-subunit combination is responsible for GHB efficacy, and the β 1 -subunit for potency. The EC 50 for GHB is 140 nM. It is concluded that GHB is a partial agonist at this site because its maximum efficacy at this recombinant receptor is 74% of that displayed by GABA. Results from pharmacological and α-subunit mutation experiments demonstrate that NCS-382 and GHB bind to the interface of the β-α combination at a site that overlaps with but is not identical to the GABA A receptor recognition site. The finding of a significant reduction in the B max for [ 3 H]NCS-382 binding in the brains of α 4 -but not δ-subunit KO mice provides further evidence that the α 4 -subunit is a molecular target for GHB. The authors propose that α 4 -containing GABA A receptors, in particular α 4 β 1 δ, represent the primary site of action for GHB. The fact that the functional response to GHB requires the presence of a δ-subunit, which is associated with only a minor fraction of GABA A receptors, but the binding site is located at the β-α interface, which is present in a large number of GABA A receptors, explains why some [ deletion of α 4 -subunits. An alternative explanation is that this residual [ 3 H]NCS-382 binding represents attachment to other molecularly, and possibly functionally, distinct GHB receptors. Among these might be the G protein-coupled GHB site reported by others (18) . Nonetheless, the findings of Absalom et al. (2) provide direct evidence that at least some of the pharmacological effects of GHB are due to its activation of extrasynaptic GABA A receptors.
Synaptic GABA A receptors mediate fast phasic inhibition, have a lower affinity for GABA than the extrasynaptic sites, and are responsible for tonic inhibition. Because of their higher affinity for GABA, extrasynaptic receptors are continuously activated by the small amounts of endogenous GABA present in the local environment. Whereas the most abundant synaptic receptor is composed of α-, β-, and γ-subunits, the extrasynaptic site contains α 4 -or α 6 -, β-, and δ-subunits (25) . Extrasynaptic GA-BA A receptors are targets for steroids, ethanol, general anesthetics, convulsants, hypnotics, and analgesics (26) . The rigid GABA analog 4,5,6,7-tetrahydroisoxazolo (5,4-c)pyridine-3-(-ol) (THIP) is an example of an extrasynaptic GABA A receptor agonist (27) . Like GHB, THIP activates αβδ-containing GABA A receptors and displays a range of interesting CNS effects.
The discovery that the effects of GHB are due to an interaction with extrasynaptic α 4 β 1 δ GABA A receptors opens the way to designing more selective agents for this site. The synthesis of such compounds could lead to the development of a new class of drugs for the treatment of anxiety, pain, insomnia, epilepsy, and other conditions associated with GABAergic dysfunction.
